Replies to Post #218267 onBiotech Values

Replies to #218267 on Biotech Values

04/04/18 5:37 PM

#218295 RE: DewDiligence #218267

Well, this is also my little critique, their delivery device only reaches 15mm deep, so it may work for melanoma, but any other form of cancer will have to wait for their next gen delivery device (of which we do not know so much).

However, since it's some kind of in-situ vaccination, IMHO the chances of an abscopal effect are much higher than with non-patient specific neoantigens (I do not find the reference, but some other company tested gp100 as neoantigen in melanoma with catastrophal results: loss of more patient specific TCR repertoire, reduced immune infiltration of the tumor and longlasting attraction of T-cells at the place of vaccination, since what was delivered there did not completely vanish).

Well, let's see.

DewDiligence

11/06/18 9:57 AM

#221975 RE: DewDiligence #218267

ONCS -54% on SITC-related PR and CC:

https://finance.yahoo.com/news/oncosec-reports-preliminary-data-keynote-130000623.html

ONCS’ TAVO + Keytruda had ORR=22% (2/9) in second-line Stage-II/IV melanoma (following PD-1 monotherapy in the first line).

Holding a CC to tout these interim data was probably a bad idea.

swampboots

11/06/18 11:30 AM

#221983 RE: DewDiligence #218267

Although Shamans need apply and are equally eligible to make abscopal treatments (by their recommendation) more "charismatic", data mining will eventually be piling up to measure the effectiveness of the abscopal effect. :

"Whereas these reports were extremely rare throughout the 20th century, the clinical use of immune checkpoint blocking antibodies such as ipilimumab or pembrolizumab has greatly increased the number of abscopally responding patients in selected groups of patients such as those with metastatic melanoma" (from Wikipedia).